Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 5 August 1977:
Vol. 197. no. 4303, pp. 596 - 598
DOI: 10.1126/science.877576
Prev | Table of Contents | Next

Articles

Science, Vol 197, Issue 4303, 596-598
Copyright © 1977 by American Association for the Advancement of Science

articles

Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity

I Creese, DR Burt, and SH Snyder

The binding of [3H]haloperidol to rat striatal dopamine receptors increases after lesion (made by injection of 6-hydroxydopamine) of the nigrostriatal dopamine pathway in those rats which are behaviorally supersensitive, as reflected by apomorphine-induced contralateral rotations. The enhanced binding is associated with an increased number of receptor sites with no change in their affinity.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.
D. Marazziti, S. Mandillo, C. Di Pietro, E. Golini, R. Matteoni, and G. P. Tocchini-Valentini (2007)
PNAS 104, 9846-9851
   Abstract »    Full Text »    PDF »
Role of Dopaminergic Treatment in Dopamine Receptor Down-regulation in Advanced Parkinson Disease: A Positron Emission Tomographic Study.
S. Thobois, F. Vingerhoets, V. Fraix, J. Xie-Brustolin, H. Mollion, N. Costes, P. Mertens, A.-L. Benabid, P. Pollak, and E. Broussolle (2004)
Arch Neurol 61, 1705-1709
   Abstract »    Full Text »    PDF »
Persistent Increase in Olfactory Type G-Protein {alpha} Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease.
J.-C. Corvol, M.-P. Muriel, E. Valjent, J. Feger, N. Hanoun, J.-A. Girault, E. C. Hirsch, and D. Herve (2004)
J. Neurosci. 24, 7007-7014
   Abstract »    Full Text »    PDF »
Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease.
E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, D. Guilloteau, A. R. Crossman, B. Bioulac, J. M. Brotchie, and C. E. Gross (2001)
J. Neurosci. 21, 6853-6861
   Abstract »    Full Text »    PDF »
Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2 Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats.
G. Cai, X. Zhen, K. Uryu, and E. Friedman (2000)
J. Neurosci. 20, 1849-1857
   Abstract »    Full Text »    PDF »
Methamphetamine-Induced Neurotoxicity Alters Locomotor Activity, Stereotypic Behavior, and Stimulated Dopamine Release in the Rat.
T. L. Wallace, G. A. Gudelsky, and C. V. Vorhees (1999)
J. Neurosci. 19, 9141-9148
   Abstract »    Full Text »    PDF »
Modulation of Rat Rotational Behavior by Direct Gene Transfer of Constitutively Active Protein Kinase C into Nigrostriatal Neurons.
S. Song, Y. Wang, S.-Y. Bak, M. J. During, J. Bryan, O. Ashe, D. B. Ullrey, L. E. Trask, F. D. Grant, K. L. O'Malley, et al. (1998)
J. Neurosci. 18, 4119-4132
   Abstract »    Full Text »    PDF »
Imaging of D2 Dopamine Receptors of Patients With Parkinson's Disease Using Single Photon Emission Computed Tomography and lodobenzamide I 123.
V. Laulumaa, J. T. Kuikka, H. Soininen, K. Bergstrom, E. Lansimies, and P. Riekkinen (1993)
Arch Neurol 50, 509-512
   Abstract »    PDF »
Drug and neurotransmitter receptors in the brain.
S. Snyder (1984)
Science 224, 22-31
   Abstract »    PDF »
Normalization of spiroperidol binding in the denervated rat striatum by homologous grafts of substantia nigra.
W. Freed, G. Ko, D. Niehoff, M. Kuhar, B. Hoffer, L Olson, H. Cannon-Spoor, J. Morihisa, and R. Wyatt (1983)
Science 222, 937-939
   Abstract »    PDF »
Cerebral Glucography With Positron Tomography: Use in Normal Subjects and in Patients With Schizophrenia.
M. S. Buchsbaum, D. H. Ingvar, R. Kessler, R. N. Waters, J. Cappelletti, D. P. van Kammen, A. C. King, J. L. Johnson, R. G. Manning, R. W. Flynn, et al. (1982)
Arch Gen Psychiatry 39, 251-259
   Abstract »    PDF »
Dopamine receptor binding is increased in diabetic rats.
D Lozovsky, C. Saller, and I. Kopin (1981)
Science 214, 1031-1033
   Abstract »    PDF »
Drug-Induced and Other Orofacial-Cervical Dyskinesias.
J. JANKOVIC (1981)
Ann Intern Med 94, 788-793
   Abstract »    PDF »
Lithium reduces the number of acetylcholine receptors in skeletal muscle.
A Pestronk and D. Drachman (1980)
Science 210, 342-343
   Abstract »    PDF »
Prostaglandins, Platelets, and Schizophrenia.
J. Rotrosen, A. D. Miller, D. Mandio, L. J. Traficante, and S. Gershon (1980)
Arch Gen Psychiatry 37, 1047-1054
   Abstract »    PDF »
Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model.
R. Hruska and E. Silbergeld (1980)
Science 208, 1466-1468
   Abstract »    PDF »
Mode of Action of Lithium: Some Biological Considerations.
W. E. Bunney Jr, A. Pert, J. Rosenblatt, C. B. Pert, and D. Gallaper (1979)
Arch Gen Psychiatry 36, 898-901
   Abstract »    PDF »
Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system.
M. Perlow, W. Freed, B. Hoffer, A Seiger, L Olson, and R. Wyatt (1979)
Science 204, 643-647
   Abstract »    PDF »
Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
A Pert, J. Rosenblatt, C Sivit, C. Pert, and W. Bunney Jr (1978)
Science 201, 171-173
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)